tiprankstipranks
Trending News
More News >
Eagle Pharmaceuticals Inc (EGRX)
OTHER OTC:EGRX
US Market

Eagle Pharmaceuticals (EGRX) Stock Statistics & Valuation Metrics

Compare
211 Followers

Total Valuation

Eagle Pharmaceuticals has a market cap or net worth of $29.22M. The enterprise value is ―.
Market Cap$29.22M
Enterprise Value

Share Statistics

Eagle Pharmaceuticals has 12,986,971 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,986,971
Owned by Insiders17.60%
Owned by Institutions0.10%

Financial Efficiency

Eagle Pharmaceuticals’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)
Return on Assets (ROA)
Return on Invested Capital (ROIC)
Return on Capital Employed (ROCE)
Revenue Per Employee2.36M
Profits Per Employee265.99K
Employee Count134
Asset Turnover
Inventory Turnover

Valuation Ratios

The current PE Ratio of Eagle Pharmaceuticals is ―. Eagle Pharmaceuticals’s PEG ratio is ―.
PE Ratio
PS Ratio0.00
PB Ratio
Price to Fair Value
Price to FCF
Price to Operating Cash Flow
PEG Ratio

Income Statement

In the last 12 months, Eagle Pharmaceuticals had revenue of 316.61M and earned 35.64M in profits. Earnings per share was 2.76.
Revenue316.61M
Gross Profit221.67M
Operating Income80.96M
Pretax Income61.43M
Net Income35.64M
EBITDA77.50M
Earnings Per Share (EPS)2.76

Cash Flow

In the last 12 months, operating cash flow was -9.32M and capital expenditures -74.00K, giving a free cash flow of -9.39M billion.
Operating Cash Flow-9.32M
Free Cash Flow-9.39M
Free Cash Flow per Share-0.72

Dividends & Yields

Eagle Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta-1.57
52-Week Price Change-38.86%
50-Day Moving Average1.72
200-Day Moving Average1.65
Relative Strength Index (RSI)65.08
Average Volume (3m)8.37K

Important Dates

Eagle Pharmaceuticals upcoming earnings date is Nov 4, 2024, TBA Not Confirmed.
Last Earnings DateAug 6, 2024
Next Earnings DateNov 4, 2024
Ex-Dividend Date

Financial Position

Eagle Pharmaceuticals as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio
Quick Ratio
Debt to Market Cap
Net Debt to EBITDA
Interest Coverage Ratio

Taxes

In the past 12 months, Eagle Pharmaceuticals has paid 25.79M in taxes.
Income Tax25.79M
Effective Tax Rate

Enterprise Valuation

Eagle Pharmaceuticals EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales
EV to EBITDA
EV to Free Cash Flow
EV to Operating Cash Flow

Balance Sheet

Eagle Pharmaceuticals has $15.35M in cash and marketable securities with $71.61M in debt, giving a net cash position of $56.26M billion.
Cash & Marketable Securities$15.35M
Total Debt$71.61M
Net Cash$56.26M
Net Cash Per Share$4.33
Tangible Book Value Per Share

Margins

Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin
Operating Margin
Pretax Margin
Net Profit Margin
EBITDA Margin
EBIT Margin

Analyst Forecast

The average price target for Eagle Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart ScoreN/A
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis